Mechanisms of action and resistance to tubulin-binding agents

Bibliography

• HASTIE SB: Interactions of colchicine with tubulin.Pharmacol. Ther. (1991) 51:377–401.
   PubMed Web of Science ®Google Scholar
• MALKINSON FD: Colchicine. New uses for an old, olddrug. Arch. Dermatol. (1982) 118:453–457.
   PubMed Web of Science ®Google Scholar
• BORISY GG, TAYLOR EW: The mechanism of action of colchicine. Colchicine binding to sea urchin eggs and the mitotic apparatus. J. Cell Biol. (1967) 34:535–548.
   Google Scholar
• LITTLE M, SEEHAUS T: Comparative analysis of tubulin sequences. Comp. Biochem. Physiol. (1988) 90:655–670.
   Google Scholar
• ABELOFF MD: Vinorelbine (Navelbine) in the treatment of breast cancer: a summary. Sem. Oncol (1995) 22:1–4.
   PubMed Web of Science ®Google Scholar
• COLTMAN CA, Jr.: Vinorelbine (Navelbine) a new agent for the treatment of non-small cell lung cancer: a summary. Sem. Oncol. (1994) 21:1–3.
   PubMed Web of Science ®Google Scholar
• DUMONTET C, BASTION Y, FELMAN P et al: Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen. Ann. Oncol. (1992) 3:639–644.
   PubMed Web of Science ®Google Scholar
• SAMSON D, GAMINARA E, NEWLAND A et al.: Infusion ofvincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma [see comments]. Lancet (1989) 2:882–885.
   PubMed Web of Science ®Google Scholar
• JORDAN MA, THROWER D, WILSON L: Mechanism ofinhibition of cell proliferation by Vinca alkaloids. Cancer Res. (1991) 51:2212–2222.
   PubMed Web of Science ®Google Scholar
• JORDAN MA, TOSO RJ, THROWER D, WILSON L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. ScL USA (1993) 90:9552–9556.
   PubMed Web of Science ®Google Scholar
• KIRSCHNER MW: Microtubule assembly and nuclea-tion. Int. Rev. Cytol. (1978) 54:1–71.
   PubMedGoogle Scholar
• ZHENG Y, JUNG MK, OAKLEY BR: Gamma-tubulin is present in Drosophila melanogaster and Homo sapiens and is associated with the centrosome. Cell (1991) 65:817–823.
   PubMed Web of Science ®Google Scholar
• CHANG P, STEARNS T: Delta-tubulin and varepsilon-tubulin: two new human centrosomal tubulins reveal new aspects of centrosome structure and function. Nature Cell Biol. (2000) 2:30–35.
   PubMed Web of Science ®Google Scholar
• TIAN G, HUANG Y, ROMMELAERE H, VANDERKERCK-HOVE J, AMPE C, COWAN NJ: Pathway leading to correctly folded 6-tubulin. Cell (1996) 86:287–296.
   PubMed Web of Science ®Google Scholar
• SULLIVAN KF, CLEVELAND DW: Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc. Natl. Acad. ScL USA (1986) 83:4327–4331.
   PubMed Web of Science ®Google Scholar
• LEWIS SA, GILMARTIN ME, HALL JL, COWAN NJ: Three expressed sequences within the human 6-tubulin multigene family each define a distinct isotype. j Mol Biol. (1985) 182:11–20.
   PubMed Web of Science ®Google Scholar
• COWAN NJ, LEWIS SA, SARKAR S, GU W. Functional versatility of mammalian 3-tubulin isotypes. In: The Cytoskeleton in Cell Differentiation and Development. Maccioni RB, Arechaga J (Eds.) ICSU Press (1986):157–166.
   Google Scholar
• WILDE CD, CROWTHER CE, CRIPE TP, GWO-SHU LEE M, COWAN NJ: Evidence that a human 6-tubulin pseudo-gene is derived from its corresponding mRNA. Nature (1982) 297:83–84.
   PubMed Web of Science ®Google Scholar
• DUMONTET C, VIONERY A: Expression of class VII beta tubulin in brain. Mol. Biol. Cell (1999) 10:141a.
   Google Scholar
• LUDUENA RF: Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytology (1998) 178:207–275.
   PubMed Web of Science ®Google Scholar
• GARD DL, KIRSCHNER MW: A polymer-dependent increase in phosphorylation of 6-tubulin accompanies differentiation of a mouse neuroblastoma cell line. J. Cell Biol. (1985) 100:764–774.
   PubMed Web of Science ®Google Scholar
• LEWIS SA, GU W, COWAN NJ: Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell (1987) 49:539–548.
   PubMed Web of Science ®Google Scholar
• ITOH TJ, HOTANI H: Microtubule-stabilizing activity of microtubule-associated proteins is due to increase in frequency of rescue in dynamic instability: shortening length decreases with binding of MAPs onto microtu-bules. Cell Struct. Funct. (1994) 19:279–290.
   PubMed Web of Science ®Google Scholar
• FELLOUS A, PRASAD V, OHAYON R, JORDAN MA, LUDUENA RF: Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin. J. Protein Chem. (1994) 13:381–391.
   PubMedGoogle Scholar
• CLEVELAND DW, HWO SY, KIRSCHNER MW: Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. (1977) 116:207–225.
   PubMed Web of Science ®Google Scholar
• MITCHISON T, KIRSCHNER M: Dynamic instability of microtubule growth. Nature (1984) 312:237–242.
   PubMed Web of Science ®Google Scholar
• MARGOLIS RL, WILSON L: Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell (1978) 13:1–8.
   Google Scholar
• THATTE SH, BRIDGES KR, GOLAN DE: Microtubule inhibitors differentially affect translational movement, cell surface expression and endocytosis of transferrin receptors in K562 cells. J. Cell Physiol (1994) 160:345–357.
   PubMed Web of Science ®Google Scholar
• DHAMODHARAN R, JORDAN MA, THROWER D, WILSON L, WADSWORTH P: Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol Biol. Cell (1995) 6:1215–1229.
   PubMed Web of Science ®Google Scholar
• BELOTTI D, VERGANI V, DRUDIS T et al.: Themicrotubule-affecting drug paclitaxel has antiangio-genic activity. Clin. Cancer Res. (1996) 2:1843–1849.
   PubMed Web of Science ®Google Scholar
• BELOTTI D, RIEPPI M, NICOLETTI MI et al.: Paclitaxel(Taxol) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin. Cancer Res. (1996) 2:1725–1730.
   PubMed Web of Science ®Google Scholar
• NOGALES E, WOLF SG, DOWNING KH: Structure of thealphabeta tubulin dimer by electron crystallography. Nature (1998) 391:199–203.
   PubMed Web of Science ®Google Scholar
• RAO S, KRAUSS NE, HEERDING JM et al.:3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J. Biol. Chem. (1994) 269:3132–3134.
   PubMed Web of Science ®Google Scholar
• COMBEAU C, COMMERCON A, MIOSKOWSKI C, ROUSSEAU B, AUBERT F, GOELDNER M: Predominant labeling of beta- over alpha-tubulin from porcine brain by a photoactivaTable taxoid derivative. Biochemistry (1994) 33:6676–6683.
   PubMed Web of Science ®Google Scholar
• FARRELL KW, WILSON L: Tubulin-colchicine complexes differentially opposite microtubule ends. Biochemistry (1984) 23:3741–3748.
   PubMed Web of Science ®Google Scholar
• PARNESS J, HORWITZ SB: Taxol binds to polymerized tubulin in vitro. J. Cell Biol. (1981) 91:479–487.
   PubMed Web of Science ®Google Scholar
• DERRY WB, WILSON L, JORDAN MA: Substoichiometric binding of taxol suppresses microtubule dynamics. Biochem. (1995) 34:2203–2211.
   PubMed Web of Science ®Google Scholar
• DYE RB, FINK SP, WILLIAMS RC, Jr.: Taxol-inducedflexibility of microtubules and its reversal by MAP-2 and Tau. J. Biol. Chem. (1993) 268:6847–6850.
   Google Scholar
• FALCONER MM, ECHEVERRI CJ, BROWN DL: Differentialsorting of 13 tubulin isotypes into colchicine-stable microtubules during neuronal and muscle differentia-tion of embryonal carcinoma cells. Cell Motil. Cytoskeleton (1992) 21:313–325.
   PubMedGoogle Scholar
• LOBERT S, FRANKFURTER A, CORREIA JJ: Binding of vinblastine to phosphocellulose-purified and a 6-class III tubulin: the role of nucleotides and 6-tubulin isotypes. Biochemistry (1995) 34:8050–8060.
   PubMed Web of Science ®Google Scholar
• LUDUENA RF, ROACH MC, TRCKA PP et al.: beta2-Tubulin, a form of chordate brain tubulin with lesser reactivity toward an assembly-inhibiting sulfhydryl-directed cross-linking reagent. Biochemistry (1982) 2 1:4787–4794.
   Google Scholar
• PANDA D, MILLER HP, BANERJEE A, LUDUENA RF, WILSON L: Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc. Natl. Acad. ScL USA (1994) 91:11358–11362.
   PubMed Web of Science ®Google Scholar
• LING V: Charles F. Kettering Prize. P-glycoprotein andresistance to anticancer drugs. Cancer (1992) 69:2603–2609.
   Google Scholar
• HARKER WG, SIKIC BI: Multidrug (pleiotropic)resistance in doxorubicin-selected varian the human sarcoma cell line MES-SA. Cancer Res. (1 98 5) 45:4091-4096.
   Google Scholar
• COLE SPC, SPARKS KE, FRASER K et al.: Pharmacologicalcharacterization of Multidrug Resistant MRP-transfected human tumor cells. Cancer Res. (1994) 54:5902–5910.
   PubMed Web of Science ®Google Scholar
• LORICO A, RAPPA G, FLAVELL RA, SARTORELLI AC:Double knockout of the MRP gene leads to increased drug sensitivity in vitro. CancerRes. (1996) 56:5351–5355.
   Web of Science ®Google Scholar
• SAMUELS BL, HOLLIS DR, ROSNER GL et al.: Modulationof vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A Cancer and Leukemia Group B study. Clin. Cancer Res. (1997) 3:1977–1984.
   PubMed Web of Science ®Google Scholar
• LIEBMANN JE, HAHN SM, COOK JA, LIPSCHULTZ C, MITCHELL JB, KAUFMAN DC: Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotox-icity. Cancer Res. (1993) 53:2066–2070.
   PubMed Web of Science ®Google Scholar
• CABRAL F, BARLOW SB: Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J. (1989) 3:1593–1599.
   PubMed Web of Science ®Google Scholar
• BOGGS BA, GONZALEZ-GARAY ML, O'BRIEN WE, BARLOW SB, CABRAL F: Mechanisms of cellular resistance to drugs that target microtubules. Cell Pharmacol. (1993) 1 (Suppl. 1).
   Google Scholar
• SCHIBLER MJ, BARLOW SB, CABRAL F: Elimination ofpermeability mutants from selections for drug resistance in mammalian cells. FASEB J. (1989) 3:163–168.
   PubMed Web of Science ®Google Scholar
• JORDAN MA, THROWER D, WILSON L: Effects of vinblas-tine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J. Cell Sci. (1992) 102:401–416.
   Google Scholar
• AOE K, UEOKA H, KIURA K et al.: Synergistic effect of docetaxel and vinorelbine against in vitro growth of a human small cell lung cancer cell line. In: American Association for Cancer Research. Washington, USA (1996)375.
   Google Scholar
• PHOTIOU A, SHAH P, LEONG LK, MOSS J, RETSAS S: Invitro synergy of paclitaxel (taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur. J. Cancer (1997) 33:463–470.
   PubMed Web of Science ®Google Scholar
• KNICK VC, EBERWEIN DJ, MILLER CG: Vinorelbinetartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J. Natl. Cancer Inst. (1995) 87:1072–1077.
   PubMed Web of Science ®Google Scholar
• VIALLET J, LABERGE F, MARTINS H et al.: Docetaxelalternating with cisplatin and vinorelbine: early evidence of additive activity in a Phase II trial of non small cell lung cancer. In: American Society of Clinical Oncology. Philadelphia, USA (1996)375.
   Google Scholar
• MILLER VA: Docetaxel and vinorelbine in the treatmentof advanced non-small cell lung cancer: preliminary results of a Phase I/II trial. Sem. Oncol (1997) 4\(Suppl. 14):S14–S15.
   Google Scholar
• DIERAS V, FUMOLEAU P, KALLA S, MILLET JL, AZLI N,POUILLART P: Docetaxel in combination with doxorubicin or vinorelbine. Eur. J. Cancer (1997) 33\(Suppl. 7):S20–S22.
   Google Scholar
• MONNIER A, RIVIERE A, DOUILLARD JY et al: Phase IIstudy of docetaxel and vinorelbine in chemotherapy naive patients with advanced non small cell lung carcinoma. In: American Society of Clinical Oncology. Philadelphia, USA (1996):378.
   Google Scholar
• PARIMOO D, JEFFERS S, MUGGIA FM: Severe neurotox-icity from vinoreline-paclitaxel combinations. J. Natl. Cancer Inst. (1996) 88:1079–1080.
   PubMed Web of Science ®Google Scholar
• KOUROUSIS C, KAKOLYRIS S, ANDROULAKIS N et al:Salvage chemotherapy with paclitaxel, vinorelbine and cisplatin (PVC) in anthracyclin-resistant advanced breast cancer. Am. J. Clin. Oncol (1998) 21:226–232.
   PubMed Web of Science ®Google Scholar
• PEREZ JE, MACHIAVELLI MR, ROMERO AO, VALLEJO CT:Vinorelbine and paclitaxel for locoregional advanced or metastatic non small cell lung cancer. In: American Society of Clinical Oncology. Atlanta, USA (1999):Abstract 2001.
   Google Scholar
• CABRAL F, SOBEL ME, GOTTESMAN MM: CHO mutantsresistant to colchicine, colcemid or griseofulvin have an altered beta-tubulin. Cell (1980) 20:29–36.
   PubMed Web of Science ®Google Scholar
• JAFFREZOU JP, DUMONTET C, DERRY WB et al.: Novelmechanism of resistance to paclitaxel (Taxol®) in human leukemia K562 cells by combined selection with PSC 833. Oncol. Res. (1995) 7:517–527.
   PubMed Web of Science ®Google Scholar
• DUMONTET C, JAFFREZOU JP: Resistance toMicrotubule-Targeted Cytotoxins in a K562 Leukemia Cell Variant Associated with Altered Tubulin Expres-sion and Polymerization. Elec. J. Oncol. (1999) 2:33–44.
   Google Scholar
• KAVALLARIS M, KUO DYS, BURKHART CA et al.: Taxolresistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. Clin. Invest. (1997) 100:1282–1293.
   Google Scholar
• HABER M, BURKHART CA, REGL DR, MADAFIGLIO J, NORRIS M, D., HORWITZ SB: Altered expression of M62, the class II 6-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J. Biol. Chem. (1995) 270:31269–31275.
   Google Scholar
• RANGANATHAN S, DEXTER DW, BENETATOS CA, CHAPMAN AE, TEW KD, HUDES GR: Increase of beta(Ill)-and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. (1996) 56:2584–2589.
   PubMed Web of Science ®Google Scholar
• GIANNAKAKOU P, SACKETT DL, KANG YK et al.: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. (1997) 272:17118–17125.
   PubMed Web of Science ®Google Scholar
• MONZO M, ROSELL R, SANCHEZ JJ et al.: Paclitaxelresistance in non-small cell lung cancer associated with beta tubulin gene mutations. J. Clin. Oncol. (1999) 17:1786–1793.
   PubMed Web of Science ®Google Scholar
• GELMON KA, TOLCHER A, DIAG AR et al.: Phase I study of liposomal vincristine. j Clin. Oncol. (1999) 17:697–705.
   PubMed Web of Science ®Google Scholar
• HUDES G, GREENBERG R, KRIGEL RL et al.: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol. (1992) 10:1754–1761.
   PubMed Web of Science ®Google Scholar
• SMITH DC, ESPER P, STRAWDERMAN M, REDMAN B, PIENTA KJ: Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer. J. Clin. Oncol. (1999) 17:1664–1671.
   PubMed Web of Science ®Google Scholar
• BALACHANDRAN R, TER HAAR E, LONGLEY RE, GUNASEKERA SP, HAMEL E, DAY BW: Effects of the novel microtubule stabilizing agent discodermolide on the microtubule network, nuclear morphology and viability of breast cancer cells. In: American Association for Cancer Research. Washington, USA (1996)439.
   Google Scholar
• BOLLAG DM, MCQUENEY PA, et al.: Epothilones, a newclass of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. (1995) 55:2325–2333.
   Google Scholar
• PANDA D, HIMES RH, MOORE RE, WILSON L: Unusually potent suppresssion of microtubule dynamics by cryptophycin 1: a mechanism for its antiproliferative action. Biochemistry (1997) 42:12948–12953.
   Google Scholar
• BAI R, TAYLOR GF, SCHMIDT JM et al.: Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions. Mol. Pharmacol. (1995) 47:965–976.
   PubMed Web of Science ®Google Scholar
• HAMEL E: Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin 1, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther. (1992) 55:31–51.
   PubMed Web of Science ®Google Scholar
• SMITH CD, ZHANG X, MOOBERRY SL, PATTERSON GM, MOORE RE: Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res. (1994) 54:3779–3784.
   PubMed Web of Science ®Google Scholar
• PITOT HC, MCELROY EA, REID JM et al.: Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin. Cancer Res. (1999) 5:525–531.
   PubMed Web of Science ®Google Scholar
• VERDIER-PINARD P, LAI JY, YO0 HD et al.: Stucture-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol. (1998) 53:62–76.
   Google Scholar